drugset / Trial / NCT00027885

Phase II Bevacizumab + Tax In Advanced Breast Cancer

NCT00027885 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This randomized phase II trial is to see if docetaxel with or without bevacizumab followed by surgery, radiation therapy, and combination chemotherapy works better in treating patients who have stage III or stage IV breast cancer.

Timeline

Start
2001-11
Primary completion
2005-12
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — Intravenous
Comparator Docetaxel Small molecule — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Doxorubicin Other / unclassified — Intravenous

Indications